drugset / Trial / NCT05204121
Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers
RandomizedSequentialOpen-labelTreatment
Summary
A randomized once weekly dose for 8 weeks, study in Healthy HIV-Uninfected Volunteers. Each of 3 parallel groups (40 mg, 80 mg and 160mg) enrolls 12 subjects.
Timeline
- Start
- 2018-12-18
- Primary completion
- 2019-04-02
- Completion
- 2019-04-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elsulfavirine | Small molecule | 40 mg | Oral |
| Subject | Elsulfavirine | Small molecule | 80 mg | Oral |
| Subject | Elsulfavirine | Small molecule | 160 mg | Oral |